A Study of TheraT® Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is an First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of
HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+
confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.